News & Updates
Filter by Specialty:

Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women
In the interim analysis of the pivotal phase III PURPOSE 1 trial, twice-yearly subcutaneous lenacapavir, a first-in-class, high-potency HIV-1 capsid inhibitor, shows 100-percent efficacy and superiority to background HIV (bHIV*) incidence and daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF**) for pre-exposure prophylaxis (PrEP) in HIV-negative cisgender women.
Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women
12 Aug 2024
Score model predicts prognosis in older adults with pneumonia
A new prediction score model identifies older patients with community-onset pneumonia who are nearing the end of life and need advance care planning (ACP) practices, reports a study.
Score model predicts prognosis in older adults with pneumonia
10 Aug 2024
Dolutegravir plus lamivudine suppresses HIV without HBV reactivation
The two-drug regimen dolutegravir plus lamivudine (DTG/3TC) is as good as 3- or 4-drug antiretroviral therapy (ART) regimens at keeping viral load suppressed while helping avoid hepatitis B virus (HBV) reactivation in people living with HIV-1 who have past exposure to HBV but no immunity, according to a post hoc analysis of five phase 3/3b studies.
Dolutegravir plus lamivudine suppresses HIV without HBV reactivation
07 Aug 2024
How viable is a self-administered injection in adults with HIV?
A substudy of the phase III FLAIR study has found comparable efficacy and pharmacokinetics for cabotegravir (CAB) plus rilpivirine (RPV) via subcutaneous (SC) administration relative to those via intramuscular (IM) gluteal injections among virally suppressed individuals living with HIV-1.
How viable is a self-administered injection in adults with HIV?
05 Aug 2024
Extended TB surveillance needed for specific IGRA-negative individuals
Certain individuals initially testing negative for tuberculosis (TB) by interferon-gamma release assay (IGRA) may later contract the infection and therefore require extended follow-up due to increased risk, as reported in a study from Singapore.